A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD

Introduction: Finerenone demonstrated kidney and cardiovascular benefits in participants with chronic kidney disease (CKD) and type 2 diabetes (T2D) on optimized renin-angiotensin system (RAS) inhibition in FIDELITY, a pooled individual-level analysis of 2 clinical trials. Considering that treatment...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Ajay K. Singh, Stefan D. Anker, Bertram Pitt, Peter Rossing, Luis M. Ruilope, Christiane Ahlers, Youssef M.K. Farag, Marc Lambelet, Meike D. Brinker, Katja Rohwedder, Gerasimos Filippatos
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Elsevier 2026-03-01
Цуврал:	Kidney International Reports
Нөхцлүүд:	chronic kidney disease finerenone glucagon-like peptide-1 receptor agonist sodium-glucose cotransporter-2 inhibitor type 2 diabetes urine albumin-to-creatinine ratio
Онлайн хандалт:	http://www.sciencedirect.com/science/article/pii/S2468024925007156
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!